Project Description:
This study is a three-arm, randomized, double-blind, placebo-controlled study of the efficacy and safety of two trough-rangest of everolimus as adjunctive therapy in patients with tuberous sclerosis complex (TSC) who have refractory partial-onset seizures.
Keyword(s):
TSC seizures, TSC epilepsy, mTOR inhibitor, RAD001, Everolimus
Core Function(s):
Performing Research or Evaluation
Area of Emphasis
Health-Related Activities, Quality of Life
Target Audience:
Professionals and Para-Professionals, Family Members/Caregivers, General Public
Unserved or Under-served Populations:
None
Primary Target Audience Geographic Descriptor:
Mulit-County
COVID-19 Related Data:
N/A